ZIOPHARM Oncology, Inc. (ZIOPHARM) is a biopharmaceutical company that focuses on the discovery and development of new cancer therapies. ZIOPHARM is applying its technologies in cancer research to develop therapeutics for patients. The Company�s portfolio consists of five clinical-stage product candidates, as well as multiple research-stage candidates. ZIOPHARM�s clinical programs include palifosfamide (ZIO-201), IL-12 DNA, indibulin (ZIO-301) and darinaparsin (ZIO-101). Palifosfamide (ZIO-201) is a deoxyribonucleic acid (DNA)-targeted cancer treatment that bypasses drug resistance mediated by aldehyde dehydrogenase (ALDH), an enzyme associated with cancer stem cells, and has a favorable toxicity profile. IL-12 DNA is a DNA therapeutic that is delivered to the patient's tumor and expresses interleukin-12, a protein that controls anti-cancer immune responses.